Safety and Efficacy Study of Mini-Dose Glucagon (G-Pen Mini) in Patients With Type 1 Diabetes
Status:
Completed
Trial end date:
2014-11-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to demonstrate that mini-doses of stable liquid glucagon (G-Pen
Mini) produced by Xeris Pharmaceuticals are safe and effective as a treatment for mild to
moderate hypoglycemia, a complication of diabetes.
Phase:
Phase 2
Details
Lead Sponsor:
Xeris Pharmaceuticals
Collaborators:
Emissary International LLC National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)